Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID.
PANTOPRAZOLE SODIUM vs PREVACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor